• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association between Influenza Vaccination and Reduced Risks of Major Adverse Cardiovascular Events in Elderly Patients
Conclusions Results of this study suggest that influenza vaccination is associated with reduced primary MACE risks in the elderly population, including those with ILI.
Source: American Heart Journal - August 2, 2017 Category: Cardiology Source Type: research

Addressing barriers to optimal oral anticoagulation use and persistence among patients with atrial fibrillation: Proceedings, Washington, DC, December 3-4, 2012
Approximately half of patients with atrial fibrillation and with risk factors for stroke are not treated with oral anticoagulation (OAC), whether it be with vitamin K antagonists (VKAs) or novel OACs (NOACs); and of those treated, many discontinue treatment. Leaders from academia, government, industry, and professional societies convened in Washington, DC, on December 3-4, 2012, to identify barriers to optimal OAC use and adherence and to generate potential solutions. Participants identified a broad range of barriers, including knowledge gaps about stroke risk and the relative risks and benefits of anticoagulant therapies;...
Source: American Heart Journal - April 25, 2014 Category: Cardiology Authors: Paul L. Hess, Michael J. Mirro, Hans-Christoph Diener, John W. Eikelboom, Sana M. Al-Khatib, Elaine M. Hylek, Hayden B. Bosworth, Bernard J. Gersh, Daniel E. Singer, Greg Flaker, Jessica L. Mega, Eric D. Peterson, John S. Rumsfeld, Benjamin A. Steinberg, Tags: Results of Expert Meetings Source Type: research

Claims-based cardiovascular outcome identification for clinical research: Results from seven large randomized cardiovascular clinical trials
ConclusionsClaims- vs. site-based (+CEC) follow-up identified similar overall cardiovascular event rates, despite meaningful differences in the events detected. Randomized treatment effects were similar using the two methods, suggesting claims data could be used to support clinical research leveraging routinely-collected data. This approach may lead to more effective evidence generation, synthesis, and appraisal of medical products and inform the strategic approaches toward the National Evaluation System for Health Technology.
Source: American Heart Journal - September 12, 2019 Category: Cardiology Source Type: research

Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials
ConclusionsClaims- versus site-based (+CEC) follow-up identified similar overall cardiovascular event rates despite meaningful differences in the events detected. Randomized treatment effects were similar using the 2 methods, suggesting claims data could be used to support clinical research leveraging routinely collected data. This approach may lead to more effective evidence generation, synthesis, and appraisal of medical products and inform the strategic approaches toward the National Evaluation System for Health Technology.
Source: American Heart Journal - November 12, 2019 Category: Cardiology Source Type: research

Rationale and design of a randomized trial of automated hovering for post-myocardial infarction patients: The HeartStrong program
Conclusions Our randomized controlled trial of the HeartStrong program will provide an evaluation of a state-of-the-art behavioral economic intervention with a number of important pragmatic features. These include a tailored intervention responding to patient activity, streamlining of consent and implementation processes using new technologies, outcomes centrally important to patients, and the ability to implement rapid-cycle innovation.
Source: American Heart Journal - July 8, 2016 Category: Cardiology Source Type: research

Rationale and design of a randomized trial of automated hovering for post –myocardial infarction patients: The HeartStrong program
Conclusions Our randomized controlled trial of the HeartStrong program will provide an evaluation of a state-of-the-art behavioral economic intervention with a number of important pragmatic features. These include a tailored intervention responding to patient activity, streamlining of consent and implementation processes using new technologies, outcomes centrally important to patients, and the ability to implement rapid-cycle innovation.
Source: American Heart Journal - July 27, 2016 Category: Cardiology Source Type: research

10-year nationwide trends of the incidence, prevalence, and adverse outcomes of non-valvular atrial fibrillation nationwide health insurance data covering the entire Korean population
Conclusions The burden of AF among Asian patients is increasing. Although the overall risks of cardiovascular events and death following AF onset have decreased over a decade, the event rates are still high. Optimized management of any associated comorbidities should be part of the holistic management approach for patients with AF.
Source: American Heart Journal - May 24, 2018 Category: Cardiology Source Type: research

Differences in Statin Utilization and Lipid-Lowering by Race, Ethnicity, and HIV Status in a Real-World Cohort of Persons with Human Immunodeficiency Virus and Uninfected Persons
ConclusionsAmong PWH with statin indication(s), Blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin utilized for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - December 21, 2018 Category: Cardiology Source Type: research

Differences in statin utilization and lipid lowering by race, ethnicity, and HIV status in a real-world cohort of persons with human immunodeficiency virus and uninfected persons
ConclusionsAmong PWH with statin indication(s), blacks and Hispanics were less likely than whites to have been prescribed a statin. These racial/ethnic disparities were less pronounced among uninfected persons. There were significant differences in type of statin used for PWH compared to uninfected matched controls. Future efforts addressing disparities in CVD prevention among PWH are warranted.
Source: American Heart Journal - January 25, 2019 Category: Cardiology Source Type: research